LAB
Price
$0.64
Change
-$0.01 (-1.54%)
Updated
Oct 22 closing price
Capitalization
249.52M
12 days until earnings call
Intraday BUY SELL Signals
RGEN
Price
$178.71
Change
-$1.30 (-0.72%)
Updated
Oct 22 closing price
Capitalization
10.09B
5 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

LAB vs RGEN

LAB vs RGEN Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
LAB vs. RGEN commentary
Oct 23, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is LAB is a Hold and RGEN is a StrongBuy.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for LAB with price predictions
Oct 22, 2026

LAB sees MACD Histogram crosses below signal line

LAB saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on October 07, 2026. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 55 instances where the indicator turned negative. In 49 of the 55 cases the stock moved lower in the days that followed. This puts the odds of a downward move at 89%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on October 06, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on LAB as a result. In 79 of 95 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 83%.

LAB moved below its 50-day moving average on October 06, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for LAB crossed bearishly below the 50-day moving average on October 08, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 16 of 20 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 80%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where LAB declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.

Bullish Trend Analysis

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 11 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a +4.76% 3-day Advance, the price is estimated to grow further. Considering data from situations where LAB advanced for three days, in 196 of 240 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.

LAB may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

The Aroon Indicator entered an Uptrend today. In 110 of 123 cases where LAB Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 89%.

Fundamental Analysis (Ratings)

The Tickeron SMR rating for this company is 50 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Valuation Rating of 59 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.462) is normal, around the industry mean (2.874). P/E Ratio (2.889) is within average values for comparable stocks, (2.324). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.052). Dividend Yield (0.000) settles around the average of (0.009) among similar stocks. P/S Ratio (3.300) is also within normal values, averaging (40.124).

The Tickeron PE Growth Rating for this company is 71 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Seasonality Score of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Price Growth Rating for this company is 80 (best 1 - 100 worst), indicating slightly worse than average price growth. LAB’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. LAB’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

A.I.Advisor
a Summary for RGEN with price predictions
Oct 22, 2026

RGEN in upward trend: price may ascend as a result of having broken its lower Bollinger Band on October 07, 2026

RGEN may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 30 of 40 cases where RGEN's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 75%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on October 20, 2026. You may want to consider a long position or call options on RGEN as a result. In 63 of 90 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 70%.

RGEN moved above its 50-day moving average on October 19, 2026 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for RGEN crossed bullishly above the 50-day moving average on October 22, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 10 of 17 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 59%.

Following a +2.03% 3-day Advance, the price is estimated to grow further. Considering data from situations where RGEN advanced for three days, in 226 of 308 cases, the price rose further within the following month. The odds of a continued upward trend are 73%.

Bearish Trend Analysis

The 10-day RSI Indicator for RGEN moved out of overbought territory on September 30, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 25 similar instances where the indicator moved out of overbought territory. In 18 of the 25 cases, the stock moved lower in the following days. This puts the odds of a move lower at 72%.

The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.

The Moving Average Convergence Divergence Histogram (MACD) for RGEN turned negative on October 02, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 52 similar instances when the indicator turned negative. In 42 of the 52 cases the stock turned lower in the days that followed. This puts the odds of success at 81%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where RGEN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 81%.

The Aroon Indicator for RGEN entered a downward trend on September 21, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is 38 (best 1 - 100 worst), indicating steady price growth. RGEN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron SMR rating for this company is 88 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is 96 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 98 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.775) is normal, around the industry mean (4.961). RGEN's P/E Ratio (241.500) is considerably higher than the industry average of (37.232). Projected Growth (PEG Ratio) (1.935) is also within normal values, averaging (4.143). Dividend Yield (0.000) settles around the average of (0.005) among similar stocks. P/S Ratio (12.469) is also within normal values, averaging (56.876).

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. RGEN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

FUNDAMENTALS RATINGS
LAB vs RGEN: Fundamental Ratings
LAB
RGEN
OUTLOOK RATING
1..100
6123
VALUATION
overvalued / fair valued / undervalued
1..100
59
Fair valued
98
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
5088
PRICE GROWTH RATING
1..100
8038
P/E GROWTH RATING
1..100
7196
SEASONALITY SCORE
1..100
7550

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

LAB's Valuation (59) in the Medical Specialties industry is somewhat better than the same rating for RGEN (98) in the Biotechnology industry. This means that LAB’s stock grew somewhat faster than RGEN’s over the last 12 months.

LAB's Profit vs Risk Rating (100) in the Medical Specialties industry is in the same range as RGEN (100) in the Biotechnology industry. This means that LAB’s stock grew similarly to RGEN’s over the last 12 months.

LAB's SMR Rating (50) in the Medical Specialties industry is somewhat better than the same rating for RGEN (88) in the Biotechnology industry. This means that LAB’s stock grew somewhat faster than RGEN’s over the last 12 months.

RGEN's Price Growth Rating (38) in the Biotechnology industry is somewhat better than the same rating for LAB (80) in the Medical Specialties industry. This means that RGEN’s stock grew somewhat faster than LAB’s over the last 12 months.

LAB's P/E Growth Rating (71) in the Medical Specialties industry is in the same range as RGEN (96) in the Biotechnology industry. This means that LAB’s stock grew similarly to RGEN’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
LABRGEN
RSI
ODDS (%)
N/A
Bearish Trend 1 day ago
72%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
85%
Bearish Trend 1 day ago
83%
Momentum
ODDS (%)
Bearish Trend 1 day ago
83%
Bullish Trend 1 day ago
70%
MACD
ODDS (%)
Bearish Trend 1 day ago
89%
Bearish Trend 1 day ago
81%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
86%
Bearish Trend 1 day ago
80%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
84%
Bearish Trend 1 day ago
81%
Advances
ODDS (%)
Bullish Trend 18 days ago
82%
Bullish Trend 2 days ago
73%
Declines
ODDS (%)
Bearish Trend 15 days ago
88%
Bearish Trend 15 days ago
81%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
85%
Bullish Trend 1 day ago
75%
Aroon
ODDS (%)
Bullish Trend 1 day ago
89%
Bearish Trend 2 days ago
86%
COMPARISON
Comparison
Oct 23, 2026
Stock price -- (LAB: $0.64 vs. RGEN: $178.71)
Brand notoriety: LAB and RGEN are both not notable
LAB represents the Medical/Nursing Services, while RGEN is part of the Pharmaceuticals: Other industry
Current volume relative to the 65-day Moving Average: LAB: 110% vs. RGEN: 112%
Market capitalization -- LAB: $249.52M vs. RGEN: $10.09B
LAB [@Medical/Nursing Services] is valued at $249.52M. RGEN’s [@Pharmaceuticals: Other] market capitalization is $10.09B. The market cap for tickers in the [@Medical/Nursing Services] industry ranges from $837 to $173.92B. The market cap for tickers in the [@Pharmaceuticals: Other] industry ranges from $126 to $156.8B. The average market capitalization across the [@Medical/Nursing Services] industry is $5.7B. The average market capitalization across the [@Pharmaceuticals: Other] industry is $9.45B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

LAB’s FA Score shows that 0 FA rating(s) are green while RGEN’s FA Score has 0 green FA rating(s).

  • LAB’s FA Score: 0 green, 5 red.
  • RGEN’s FA Score: 0 green, 5 red.
According to our system of comparison, LAB is a better buy in the long-term than RGEN.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

LAB’s TA Score shows that 4 TA indicator(s) are bullish while RGEN’s TA Score has 5 bullish TA indicator(s).

  • LAB’s TA Score: 4 bullish, 5 bearish.
  • RGEN’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, RGEN is a better buy in the short-term than LAB.

Price Growth

LAB (@Medical/Nursing Services) experienced а -3.46% price change this week, while RGEN (@Pharmaceuticals: Other) price change was -2.96% for the same time period.

The average weekly price growth across all stocks in the @Medical/Nursing Services industry was -1.50%. For the same industry, the average monthly price growth was -10.64%, and the average quarterly price growth was -10.25%.

The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was +0.59%. For the same industry, the average monthly price growth was -3.91%, and the average quarterly price growth was +7.47%.

Reported Earning Dates

LAB is expected to report earnings on Nov 03, 2026.

RGEN is expected to report earnings on Oct 27, 2026.

Industries' Descriptions

@Medical/Nursing Services (-1.50% weekly)

The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.

@Pharmaceuticals: Other (+0.59% weekly)

Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.

View a ticker or compare two or three
LAB
Daily Signal:
Gain/Loss:
RGEN
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
MIG20.580.22
+1.10%
VanEck Moody's Analytics IG Corporate Bond ETF (MIG)
VYM162.601.15
+0.71%
Vanguard High Dividend Yield Index ETF (VYM)
XEMD43.210.10
+0.23%
BondBloxx JP Morgan USD Emerging Markets 1-10 Year Bond ETF (XEMD)
IBIC25.68N/A
N/A
iShares iBonds Oct 2026 Term TIPS ETF (IBIC)
SPTE46.16-1.86
-3.87%
SP Funds S&P Global Technology ETF (SPTE)